MaxCyte Signs Strategic Platform License with Adicet Bio for Cancer and Autoimmune Diseases Treatments.

MaxCyte has signed a strategic platform license with Adicet Bio to use its Flow Electroporation technology and ExPERT platform for research, clinical, and commercial purposes. Adicet will use MaxCyte's technology to develop allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. The agreement grants Adicet non-exclusive rights to use MaxCyte's ExPERT technology for large-scale production of off-the-shelf cell therapies.

Title: MaxCyte Partners with Adicet Bio to Advance Gamma Delta T Cell Therapies

MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company, has signed a strategic platform license agreement with Adicet Bio, Inc. to support the development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. The agreement grants Adicet Bio non-exclusive rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for research, clinical, and commercial purposes [1].

Under the terms of the agreement, Adicet Bio will utilize MaxCyte's technology to enhance its proprietary manufacturing process, which combines non-viral gene editing with a robust expansion platform to deliver potent cell therapy products. The collaboration aims to enable scalable production of off-the-shelf, allogeneic cell therapies for various clinical applications [1].

MaxCyte's Flow Electroporation® technology and ExPERT™ platform are designed to support complex and scalable cell engineering, delivering high transfection efficiency and cell viability [2]. Maher Masoud, President and Chief Executive Officer of MaxCyte, stated, "We are pleased to support Adicet Bio as they expand their allogeneic gamma delta T cell manufacturing capabilities to include non-viral gene editing delivery. This collaboration underscores the versatility of our platform and its ability to enable the development of next-generation cell therapy candidates with increased efficiency and accessibility" [1].

MaxCyte will receive platform licensing fees and program-related revenue as part of the agreement. However, the exact terms and conditions of the agreement, including the potential revenue streams, were not disclosed [1].

The strategic platform license agreement between MaxCyte and Adicet Bio is a significant step in advancing the development of next-generation cell therapies. It highlights the potential of MaxCyte's platform technology in enabling the efficient and scalable production of cell-based therapeutics [1].

References:
[1] https://investors.maxcyte.com/news-releases/news-release-details/maxcyte-signs-platform-license-agreement-adicet-bio
[2] https://www.morningstar.com/news/globe-newswire/9504081/maxcyte-signs-platform-license-agreement-with-adicet-bio